Skip to main content
. Author manuscript; available in PMC: 2015 Feb 2.
Published in final edited form as: Acta Neuropathol. 2013 Jan 5;125(3):359–371. doi: 10.1007/s00401-012-1077-2

Figure 5. Risk-stratification using DNA methylation markers in 191 medulloblastoma patients aged 3.0 to 16.0 at diagnosis.

Figure 5

a. Current clinical (first panel) and clinical / molecular (second panel) models were assessed alongside a novel model incorporating DNA methylation biomarkers (third panel), and used to derive Kaplan-Meier plots (b). LCA, large-cell/anaplastic pathology; M+, metastatic disease; MXI1 and IL8 meth, methylated (β≥0.67). Low-risk, green; standard-risk, amber; high-risk, red. P values from log-rank tests are shown. c. Time-dependent ROC curves for all three models at 5 and 10 years. The area under the curve (AUC) is shown for each model. FP, false positive rate; TP, true positive rate. Fav, favorable.